Rational design of low-molecular weight heparins with improved in vivo activity. - Wikidata - wikimedia - TriplyDB

Rational design of low-molecular weight heparins with improved in vivo activity.

Rational design of low-molecular weight heparins with improved in vivo activity.

http://www.wikidata.org/entity/Q34470423

about

Affinity-Based Drug Delivery M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice Comparative glycomics using a tetraplex stable-isotope coded tag.Glycomics analysis of mammalian heparan sulfates modified by the human extracellular sulfatase HSulf2.Bioactive factor delivery strategies from engineered polymer hydrogels for therapeutic medicine.Biosynthesis of 3-O-sulfated heparan sulfate: unique substrate specificity of heparan sulfate 3-O-sulfotransferase isoform 5.Monitoring of heparin and its low-molecular-weight analogs by silicon field effect.Homogeneous low-molecular-weight heparins with reversible anticoagulant activity.Directing the biological activities of heparan sulfate oligosaccharides using a chemoenzymatic approach Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route.Polysaccharide-based nanoparticles for theranostic nanomedicine.Capillary electrophoresis of complex natural polysaccharides Scientific considerations in the review and approval of generic enoxaparin in the United States.Discovery of a heparan sulfate 3-O-sulfation specific peeling reaction.Conformational transitions induced in heparin octasaccharides by binding with antithrombin III.Injectable hydrogels for cartilage and bone tissue engineering.Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis.Capillary electrophoretic analysis of isolated sulfated polysaccharides to characterize pharmaceutical products Biochemical analysis and kinetic modeling of the thermal inactivation of MBP-fused heparinase I: implications for a comprehensive thermostabilization strategy.Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins.

P2860

Q29543246-3437C11F-C057-44CF-B290-88E398D93CFB Q33680964-BCE12041-5B02-4E46-9C84-EB52336D556B Q33789401-1CDAAD08-60D9-4C40-B8EF-DCF353008406 Q33828849-8B7B5EAA-F256-4A5D-98C5-DE3EB22679EA Q34204037-E4A5D04F-24A6-4356-BD10-B8EF9ACA5772 Q34220892-B41A411A-66DA-49B3-A11C-0A0FBA96089C Q35037245-CD38430D-F2EA-4258-AA85-F062F83C8274 Q35361517-8CA65A7C-94C5-4678-ACD2-96B2260AD0BD Q35591462-64599DEF-3BED-46AA-A175-C0350D597C0B Q36304924-C5A85D32-82B7-409F-84D4-0B0EF02F7D76 Q36449216-B15F3E60-4D69-4BFD-9F65-E300D1DC3D03 Q36703343-3642DAF3-9515-412E-9DAE-529E2880A2B1 Q37218824-806B5410-B1F7-428D-BBFF-616A50A2F8C5 Q38087496-5EED13DB-82AB-42A4-B5E3-516D802CE14C Q38302345-97D3F77A-23C6-47E1-A5FB-11710E973FC9 Q38312109-D3644882-FAE1-4AC5-A240-956E9DEBF4C1 Q38674409-7871F1A4-4A09-4F4B-96CE-A368D7E7B020 Q40816555-682232E9-D630-4182-9A1B-23F46F3D907A Q42129756-3ADF5E22-F60C-45D8-9DB1-07F09C2B63C9 Q46850853-6B744F49-6614-4B44-B2B7-B63A4FB2E8A0 Q47189835-6320908B-8B89-4970-B93B-4627BF549489

P2860

Rational design of low-molecular weight heparins with improved in vivo activity.

http://www.wikidata.org/entity/Q34470423

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Rational design of low-molecular weight heparins with improved in vivo activity.

@ast

Rational design of low-molecular weight heparins with improved in vivo activity.

@en

Rational design of low-molecular weight heparins with improved in vivo activity.

@nl

type

label

Rational design of low-molecular weight heparins with improved in vivo activity.

@ast

Rational design of low-molecular weight heparins with improved in vivo activity.

@en

Rational design of low-molecular weight heparins with improved in vivo activity.

@nl

prefLabel

Rational design of low-molecular weight heparins with improved in vivo activity.

@ast

Rational design of low-molecular weight heparins with improved in vivo activity.

@en

Rational design of low-molecular weight heparins with improved in vivo activity.

@nl

P1433

Q34470423-92862CB8-37AB-4D38-BA43-98D63660A9F5

P1476

Q34470423-29211C79-6142-41DA-8F79-DC7CC2DFB83E

P2093

Q34470423-0BCAAD2E-41CA-4A35-A6ED-B2142A5878DD

Q34470423-1BD67282-FD76-42FF-A93E-49B170376360

Q34470423-461F6A5F-3CC1-47CD-ADAE-DE04067079FE

Q34470423-7D8BA744-4744-4B77-A3B2-8A887655887C

Q34470423-B0264E0D-8F6A-4400-89AA-EB693759C2C4

Q34470423-BE20D332-AA02-41BB-8F3D-618C77617571

Q34470423-C0D8A387-C120-453D-B8B6-E9C2E181BC00

Q34470423-D962EE4A-ADF6-4E8C-B4F8-13CF717DE1C7

P2860

Q34470423-035B8EFE-99C4-4231-9980-BA4020C8B4BC

Q34470423-118700E8-3728-476D-9CB6-FA7C98F00671

Q34470423-1B621F9A-4102-4178-95BE-80FD5F6CFF44

Q34470423-21048098-9C52-4052-9401-861653870846

Q34470423-2699BDBF-77B1-47C4-A89E-1474011B57A3

Q34470423-2EC13C85-1120-4506-8BCF-12ADE67524AC

Q34470423-363F7F08-9D90-4ACD-B67B-B4AB52BBC23B

Q34470423-3E50E402-C49E-4C16-A4F8-5DC0C1C181A6

Q34470423-52A28F4E-6767-4F39-92C0-5217F1A57FC9

Q34470423-649699BF-3E9F-4781-9DBF-A761782FEF9C

P304

Q34470423-FA3C3091-FBF4-4F4C-83BD-E0C0C5112E4F

P31

Q34470423-3273CC33-4B02-4E14-A1B9-D3FC4433BAA2

P356

Q34470423-74110AB4-7774-48CE-B694-6731E9987A1E

P407

Q34470423-E8291AE9-27DE-41E4-95DF-9FE518B873A5

P433

Q34470423-82882EA9-8EF3-4406-A0F7-4CCA75A84FE3

P478

Q34470423-88D76288-9997-408E-99C3-B5B714D77F66

P577

Q34470423-61027BCD-EF9E-4499-BFC5-053FDE9FB926

P5875

Q34470423-65331143-8B21-4F55-96F2-841EFCA3F776

P698

Q34470423-819AB3D8-0A0E-42CD-A9E2-A2A09999DC55

P921

Q34470423-92E2F584-0A99-4820-86B8-FF364A7DFDCB

P932

Q34470423-AFC302A5-3C3E-43E5-AE40-50D91C7E32EB

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Rational design of low-molecular weight heparins with improved in vivo activity.

@en

P2093

Dongfang Liu

http://www.w3.org/2001/XMLSchema#string

Ganesh Venkataraman

http://www.w3.org/2001/XMLSchema#string

Ganlin Zhao

http://www.w3.org/2001/XMLSchema#string

Mallik Sundaram

http://www.w3.org/2001/XMLSchema#string

Ram Sasisekharan

http://www.w3.org/2001/XMLSchema#string

Robert Langer

http://www.w3.org/2001/XMLSchema#string

Yiwei Qi

http://www.w3.org/2001/XMLSchema#string

Zachary Shriver

http://www.w3.org/2001/XMLSchema#string

P2860

The anticoagulant activation of antithrombin by heparin

Sequencing complex polysaccharides.

Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin

Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site.

Heparin-induced thrombocytopenia: pathophysiology and management.

Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin.

RNA aptamers as reversible antagonists of coagulation factor IXa.

Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins.

Structural characterization of low molecular weight heparins.

Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery.

P304

651-656

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.252643299

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10952039

http://www.w3.org/2001/XMLSchema#string

P698

12525684

http://www.w3.org/2001/XMLSchema#string

P921

molecular design

P932

141051

http://www.w3.org/2001/XMLSchema#string